Akari Therapeutics PLC (AKTX)
0.98
+0.03
(+3.16%)
USD |
NASDAQ |
Dec 24, 16:00
Price Chart
Key Stats
| Price and Performance | |
|---|---|
| Market Cap | 24.26M |
| 52 Week High (Daily) | Upgrade |
| 52 Week Low (Daily) | Upgrade |
| All-Time High (Daily) | Upgrade |
| Year to Date Total Returns (Daily) | Upgrade |
| 1 Month Total Returns (Daily) | Upgrade |
| 1 Year Total Returns (Daily) | -67.87% |
| Valuation | |
| PE Ratio | -- |
| PE Ratio (Forward) | Upgrade |
| PS Ratio | -- |
| Price to Book Value | -- |
| EV to EBITDA | Upgrade |
| Dividend | |
|---|---|
| Dividend | -- |
| Dividend Yield (Forward) | Upgrade |
| Financials | |
| Revenue (5 Year Growth) | Upgrade |
| Revenue (Quarterly YoY Growth) | Upgrade |
| EPS Diluted (5 Year Growth) | Upgrade |
| EPS Diluted (Quarterly YoY Growth) | Upgrade |
| Debt to Equity Ratio | -- |
| Return on Equity | Upgrade |
| Return on Assets | Upgrade |
| Risk | |
| Beta (5Y) | Upgrade |
| Max Drawdown (5Y) | 98.67% |
Profile
| Akari Therapeutics PLC is a clinical stage biopharmaceutical company. It is focused on developing therapies for autoimmune and inflammatory diseases involving the complement component 5 (C5) and leukotriene B4 (LTB4) pathways. The company's pipelines include HSCT-TMA and Geographic Atrophy (GA). |
| URL | https://www.akaritx.com |
| Investor Relations URL | http://akaritx.com/investor-relations/ |
| HQ State/Province | Massachusetts |
| Sector | Health Care |
| Industry | Biotechnology |
| Equity Style | N/A |
| Next Earnings Release | Apr. 01, 2025 (est.) |
| Last Earnings Release | Aug. 19, 2024 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |
Ratings
Profile
| Akari Therapeutics PLC is a clinical stage biopharmaceutical company. It is focused on developing therapies for autoimmune and inflammatory diseases involving the complement component 5 (C5) and leukotriene B4 (LTB4) pathways. The company's pipelines include HSCT-TMA and Geographic Atrophy (GA). |
| URL | https://www.akaritx.com |
| Investor Relations URL | http://akaritx.com/investor-relations/ |
| HQ State/Province | Massachusetts |
| Sector | Health Care |
| Industry | Biotechnology |
| Equity Style | N/A |
| Next Earnings Release | Apr. 01, 2025 (est.) |
| Last Earnings Release | Aug. 19, 2024 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |